Cytoplasmic dynein 1 (dynein) is the primary minus end–directed motor protein in most eukaryotic cells. Dynein remains in an inactive conformation until the formation of a tripartite complex comprising dynein, its regulator dynactin, and a cargo adaptor. How this process of dynein activation occurs is unclear since it entails the formation of a three-protein complex inside the crowded environs of a cell. Here, we employed live-cell, single-molecule imaging to visualize and track fluorescently tagged dynein. First, we observed that only ∼30% of dynein molecules that bound to the microtubule (MT) engaged in minus end–directed movement, and that too for a short duration of ∼0.6 s. Next, using high-resolution imaging in live and fixed cells and using correlative light and electron microscopy, we discovered that dynactin and endosomal cargo remained in proximity to each other and to MTs. We then employed two-color imaging to visualize cargo movement effected by single motor binding. Finally, we performed long-term imaging to show that short movements are sufficient to drive cargo to the perinuclear region of the cell. Taken together, we discovered a search mechanism that is facilitated by dynein’s frequent MT binding–unbinding kinetics: (i) in a futile event when dynein does not encounter cargo anchored in proximity to the MT, dynein dissociates and diffuses into the cytoplasm, (ii) when dynein encounters cargo and dynactin upon MT binding, it moves cargo in a short run. Several of these short runs are undertaken in succession for long-range directed movement. In conclusion, we demonstrate that dynein activation and cargo capture are coupled in a step that relies on the reduction of dimensionality to enable minus end–directed transport in cellulo and that complex cargo behavior emerges from stochastic motor–cargo interactions.
Subclinical chronic kidney disease (sCKD) predisposes one to acute kidney injury (AKI) and chronic kidney disease (CKD). Reduced kidney functional reserve (KFR) detects sCKD in preclinical studies and predicts AKI after cardiac surgery. We evaluated renal protection in a rat model of kidney injury where ischaemia–reperfusion injury (IRI) was induced after sCKD. Dual treatment boosting nicotinamide adenine dinucleotide (NAD) by nicotinamide riboside (NR) combined with the mitochondria-targeted antioxidant SkQR1 protected the KFR and reduced structural kidney damage, including markers of vascular integrity and the relative blood volume (rBV). The dual treatment upregulated Sirt1 and Nrf2, increased the nuclear localisation of the mitochondrial biogenesis regulator PGC-1α and the mitochondrial protein marker COX4, and upregulated the antioxidant gene NOQ1. These observations suggest mitochondrial protection and modulation of the cellular redox state provided long-term structural and functional protection against kidney injury superimposed on background sCKD.
Membrane growth is vital to the evolution of cellular life. For model protocells, this has most commonly been shown to occur through competition between different protocell populations or with the addition of extra amphiphiles. We find an alternative mechanism for protocell membrane growth that occurs as a consequence of hypoosmotic shocks that could have occurred naturally in the protocell environment. We show that nanoscale and giant fatty acid vesicles can withstand substantial osmotic pressures through membrane growth, whilst also retaining a significant portion of their contents. Notably, the giant vesicles retained contents following osmotic shocks ten times higher than that predicted to be tolerable. This is likely enabled by the membrane’s incorporation of additional amphiphiles from less tense vesicles. The dynamic nature of these fatty acid-based model protocells provides a mechanism through which not only membrane growth occurs, but a mechanism which enables protocell survival in hypoosmotic environments.
There are no currently approved therapies that promote new myelin formation after myelin damage, which can, in part, be attributed to a lack of reliable systems that can reproducibly model these processes. Here we engineered a human iPSC-derived spheroid model enriched with mature, myelinating oligodendrocytes and functionally reactive microglia. This model enables the study of human central nervous system remyelination after a demyelinating insult by recapitulating processes of myelin damage and repair. These include myelin fragmentation, microglial reactivity and phagocytosis of myelin debris, oligodendrocyte generation and differentiation, and axonal ensheathment with newly formed myelin. We show that newly generated oligodendrocytes contribute to remyelination, and use ultrastructural quantification to demonstrate that remyelinated axons are ensheathed by thinner myelin after injury. Altogether, we provide a model to interrogate otherwise inaccessible aspects of human myelin biology relevant to multiple sclerosis, providing mechanistic insights into disease pathways and a platform for drug screening.